Dr Richard Hoglund
Head of Pharmacometrics
Richard Hoglund heads the pharmacometrics group at the department of Clinical Pharmacology, MORU. He has a background in chemical engineering and pharmacology and his research is mainly focused on pharmacometrics, pharmacokinetics, pharmacodynamics and mathematical modelling in tropical medicine research, with a particular focus on antimalarial therapy.
More specific, his main research aims to optimise current and future antimalarial therapies by utilizing pharmacometric methodologies. A pharmacometric modelling approach can identify specific groups at risk of treatment failure and the derived pharmacometric models can help to evaluate and suggest new dose regimens to improve the treatment of malaria.
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for Hepatitis C: a single arm mechanistic pilot study
Flower B. et al, (2023), eLife, 12
Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers
Chotsiri P. et al, (2022), Clinical Pharmacology & Therapeutics, 112, 824 - 835
A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics.
Wattanakul T. et al, (2022), Expert Rev Clin Pharmacol
Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
Assmus F. et al, (2022), Microorganisms, 10, 1639 - 1639
Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2
Driouich J-S. et al, (2022), eBioMedicine, 82, 104148 - 104148